查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1819986

2025-2033年經前症候群治療市場報告（依藥物類型、種類、配銷通路和地區）

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球經前症候群治療市場規模達14.43億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到19.2億美元，2025-2033年期間的複合年成長率（CAGR）為3.2%。市場成長的驅動力包括：精準醫療日益受到重視，精準醫療能夠改善患者預後並提高治療效率；醫療保健支出不斷成長，從而改善了醫療服務的可及性並擴大了治療選擇；以及女性勞動力參與率的提高。

經前症候群治療市場趨勢：

精準醫療日益受到關注

根據 IMARC 集團的報告，全球精準醫療市場規模在 2023 年將達到 752 億美元。精準醫療可以根據患者的基因特徵、荷爾蒙狀態和症狀等特徵提供量身定做的醫療干預措施。就經前症候群 (PMS) 而言，其症狀和嚴重程度因人而異，個人化治療方案可以提供更有針對性和更有效的治療。此外，與 PMS 相關的遺傳因素或生物標記有助於為每位患者量身定做最有效的治療方案。這可以改善治療效果，減少治療方案的反覆試驗。除此之外，透過根據患者的基因或生理特徵來匹配治療方案來選擇不太可能引起不良反應的藥物，正在擴大市場成長。

醫療支出不斷上漲

隨著醫療保健支出的增加，越來越多的人，包括飽受經前症候群 (PMS) 困擾的女性，能夠尋求醫療幫助，包括基層醫療醫師、婦科醫生和其他能夠對 PMS 進行適當診斷和治療的從業人員。此外，高額醫療保健支出通常與更多 PMS 治療方案的可近性相關，這些方案包括荷爾蒙療法、抗憂鬱藥物等藥物治療，以及認知行為療法或生活方式改變等非藥物療法。高額醫療保健支出為研發活動創造了更多機會，有助於找到更好的 PMS 療法。根據美國醫療保險和醫療補助服務中心 (CMS) 網站 2024 年更新的內容，醫療保健支出佔 GDP 的比重預計將從 2022 年的 17.3% 成長到 2032 年的 19.7%。

提高女性勞動參與率

根據世界銀行的數據，2023年全球女性勞動參與率為49%。隨著越來越多的女性進入職場，經前症候群（PMS）的經濟影響日益突出。由於其症狀，PMS對工作效率、出勤率和績效構成威脅。在認知到這些影響後，雇主和醫療保健提供者更有動力尋找有效的治療方法，以減少PMS對工作場所造成的干擾。此外，企業正在投資工作場所健康計劃，其中包括針對PMS等生殖健康問題的支援。這些計劃提供治療、根據症狀日期靈活安排工作時間以及教育資源，所有這些都有助於提高公眾對PMS現有治療方法的認知和使用。

經前症候群治療市場區隔：

依毒品類型分類：

  • 止痛藥
  • 抗憂鬱藥
  • 口服避孕藥和卵巢抑制劑
  • 其他

鎮痛藥佔大部分市場佔有率

經前症候群是指許多女性在月經週期前出現的一系列生理和心理症狀，例如腹痛、頭痛和肌肉疼痛。止痛藥因其能快速緩解這些症狀而廣受青睞，成為許多尋求在月經期間立即獲得舒適感的女性的首選。此外，人們越來越意識到鎮痛藥在控制疼痛方面的功效，這推動了經前症候群治療市場對止痛藥的需求。

按類型分列：

  • 處方
  • 在櫃檯

場外交易佔據產業最大佔有率

用於治療經前症候群 (PMS) 的非處方 (OTC) 產品包括止痛藥、利尿劑以及鈣和鎂等其他補充劑，無需醫生處方即可在櫃檯購買。這種便利性使女性無需就醫即可獨立治療症狀。腹脹、痙攣、疲勞和情緒波動正成為經前症候群 (PMS) 導致的嚴重問題。非處方藥可根據不同的症狀提供多種解決方案。 OTC 品牌的知名度以及從藥局、零售店和線上平台購買這些產品的便利性，促進了市場的成長。

按配銷通路細分：

  • 醫院藥房
  • 藥局和零售藥房
  • 網路商店

藥局和零售藥局是主要的細分市場

女性喜歡去藥局和藥房，因為她們可以買到各種各樣的非處方藥和補充劑來緩解經前症候群的症狀。這確保了患有經前症候群的女性能夠以最快的方式獲得緩解，而無需處方。其次，藥局和零售藥局為顧客提供各種品牌和形式的產品，可以幫助她們根據自己的需求和症狀選擇所需的產品。這種多樣性提高了個人滿意度，並確保人們能夠找到符合其特定需求的產品。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美領先市場，佔據經前症候群治療市場最大佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是經前症候群治療最大的區域市場。

根據加拿大衛生資訊研究所網站發布的一篇文章，加拿大的醫療保健支出在2023年達到3,440億美元。隨著醫療保健支出的不斷成長，用於女性健康（包括經前症候群）的專業醫療保健服務和資源也相應增加。這包括改善了獲得能夠有效診斷和治療經前症候群的醫療保健專業人員的機會，從而提高了患者對該疾病的認知和認知。此外，北美的經前症候群發生率很高，這促使對有效治療方案的需求龐大。此外，該地區經濟強勁，醫療服務和藥物的可負擔性更高，進一步推動了市場成長。

（請注意，這只是關鍵參與者的部分名單，完整名單在報告中提供。）

  • 主要參與者正在開發和推出用於管理經前症候群 (PMS) 症狀的新藥物和療法，拓展患者的治療選擇。他們進行研究並參與臨床試驗，以便更好地理解PMS的機制、驗證療效並探索新的治療方法。此外，許多公司專注於個人化醫療方法，根據患者的個別特徵量身訂做治療方案，從而改善治療效果和患者滿意度。主要參與者參與宣傳活動，以提高人們對PMS的認知，提高診斷率，並向醫療保健提供者和患者宣傳可用的治療方案。他們專注於整合數位健康技術，例如用於症狀追蹤的應用程式、穿戴式裝置和遠距醫療解決方案，以增強患者護理和治療效果。例如，2024年，Samphire Neuroscience新創公司籌集了230萬美元，利用神經科技穿戴裝置來應對PMS和經痛。

本報告回答的關鍵問題

  • 2024 年全球經前症候群治療市場規模是多少
  • 2025-2033年全球經前症候群治療市場的預期成長率是多少
  • 推動全球經前症候群治療市場的關鍵因素有哪些
  • COVID-19 對全球經前症候群治療市場有何影響
  • 根據藥物類型，全球經前症候群治療市場如何分類
  • 全球經前症候群治療市場按類型分類如何
  • 根據配銷通路，全球經前症候群治療市場如何分佈
  • 全球經前症候群治療市場的主要區域有哪些
  • 全球經前症候群治療市場的主要參與者/公司有哪些

本報告回答的關鍵問題

  • 2024年全球經前症候群治療市場規模？ 2025-2033年全球經前症候群治療市場的預期成長率是多少？
  • 推動全球經前症候群治療市場的關鍵因素有哪些？
  • COVID-19 對全球經前症候群治療市場有何影響？
  • 根據藥物類型，全球經前症候群治療市場是如何分佈的？
  • 全球經前症候群治療市場按類型分類是怎樣的？
  • 根據配銷通路，全球經前症候群治療市場如何分佈？
  • 全球經前症候群治療市場的主要地區有哪些？
  • 全球經前症候群治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球經前症候群治療市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥物類型

  • 止痛藥
  • 抗憂鬱藥
  • 口服避孕藥和卵巢抑制劑
  • 其他

第7章：市場區隔：依類型

  • 處方
  • 在櫃檯

第8章：市場區隔：按配銷通路

  • 醫院藥房
  • 藥局和零售藥房
  • 網路商店

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 10 章：SWOT 分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
Product Code: SR112025A4284

The global premenstrual syndrome treatment market size reached USD 1,443 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,920 Million by 2033, exhibiting a growth rate (CAGR) of 3.2% during 2025-2033. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the IMARC Group's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

Breakup by Drug Type:

  • Analgesics
  • Antidepressants
  • Oral Contraceptives and Ovarian Suppression Agents
  • Others

Analgesics accounts for the majority of the market share

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

  • Prescription
  • Over-the-Counter

Over-the-counter holds the largest share of the industry

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Drugs stores and retail pharmacies represent the leading market segment

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Key Questions Answered in This Report

  • 1.What was the size of the global premenstrual syndrome treatment market in 2024?
  • 2.What is the expected growth rate of the global premenstrual syndrome treatment market during 2025-2033?
  • 3.What are the key factors driving the global premenstrual syndrome treatment market?
  • 4.What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5.What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6.What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7.What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8.What are the key regions in the global premenstrual syndrome treatment market?
  • 9.Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2024
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players